{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "escitalopram" in Reference Text / Citation (exact match)
Showing 1 - 2 of 2 results
Status:
US Approved Rx
(2002)
Source:
NDA021323
(2002)
Source URL:
First approved in 2002
Source:
NDA021323
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Escitalopram is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). Escitalopram, also known by the brand names Lexapro and Cipralex among others, is an antidepressant. The mechanism of antidepressant action of escitalopram, the S-enantiomer of racemic citalopram, is presumed to
be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition
of CNS neuronal reuptake of serotonin (5-HT). In vitro and in vivo studies in animals suggest that escitalopram is
a highly selective serotonin reuptake inhibitor (SSRI) with minimal effects on norepinephrine and dopamine
neuronal reuptake. Escitalopram is at least 100-fold more potent than the R-enantiomer with respect to inhibition
of 5-HT reuptake and inhibition of 5-HT neuronal firing rate. LEXAPRO (escitalopram) is indicated for the treatment of major depressive disorder and generalized anxiety disorder .